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The stability and activity of numerous signaling pro-
teins in both normal and cancer cells depends on
the dimeric molecular chaperone heat shock protein
90 (Hsp90). Hsp90’s function is coupled to ATP bind-
ing and hydrolysis and requires a series of confor-
mational changes that are regulated by cochaper-
ones and numerous posttranslational modifications
(PTMs). SUMOylation is one of the least-understood
Hsp90 PTMs. Here, we show that asymmetric
SUMOylation of a conserved lysine residue in the N
domain of both yeast (K178) and human (K191)
Hsp90 facilitates both recruitment of the adenosine
triphosphatase (ATPase)-activating cochaperone
Aha1 and, unexpectedly, the binding of Hsp90 inhib-
itors, suggesting that these drugs associate prefer-
entially with Hsp90 proteins that are actively
engaged in the chaperone cycle. Importantly, cellular
transformation is accompanied by elevated steady-
state N domain SUMOylation, and increased Hsp90
SUMOylation sensitizes yeast and mammalian cells
to Hsp90 inhibitors, providing a mechanism to
explain the sensitivity of cancer cells to these drugs.
INTRODUCTION
The evolutionarily conserved molecular chaperone heat shock
protein 90 (Hsp90) is an essential component of the cellular
homeostatic machinery in eukaryotes (Picard, 2002; Taipale
et al., 2010). Cancer cells strongly depend on Hsp90 because
of their need to cope with constitutive genetic instability andMofrequent environmental insults, including nutrient deprivation,
hypoxia, and proteotoxic stress (Trepel et al., 2010), and
emerging clinical data identify Hsp90 inhibition as a promising
therapeutic strategy to treat cancer (Neckers and Workman,
2012). Cancer cells appear to be particularly sensitive to
Hsp90 inhibitors when compared to nontransformed cells (Bisht
et al., 2003), and these drugs are retained by tumors in vivo far
longer than in normal tissues (Trepel et al., 2010). However, the
molecular basis for these phenomena remains undefined.
The Hsp90 molecule is a dimer, and each protomer can be
divided into structurally and functionally distinct domains: (i) an
N-terminal domain that contains an ATP-binding pocket, which
can also be occupied by small molecule inhibitors, as well as
sites for cochaperone and client binding; (ii) a middle domain
that provides additional cochaperone and client-interacting
surfaces and also completes the split adenosine triphosphatase
(ATPase) motif of Hsp90; and (iii) a C-terminal domain providing
sites for constitutive dimerization and for cochaperone and client
interaction (Ali et al., 2006; Shiau et al., 2006; Stebbins et al.,
1997). Hsp90 chaperone function depends on an ordered
sequence of dynamic conformational changes that are linked
to binding and hydrolysis of ATP and are disrupted by drug
occupancy of the ATP pocket (Hessling et al., 2009; Mayer,
2010; McClellan et al., 2007; Picard, 2002; Prodromou, 2012;
Trepel et al., 2010). In eukaryotes, the Hsp90 conformational
cycle is facilitated by a number of proteins, termed cochaper-
ones, that interact with distinct Hsp90 conformations and serve
discrete functions (Cox and Johnson, 2011; Li et al., 2012).
Growing evidence suggests that Hsp90 interacts asymmetrically
with clients and some cochaperones and that each Hsp90 pro-
tomer can hydrolyze ATP independently (Cunningham et al.,
2008; Vaughan et al., 2006). A number of cochaperones (e.g.,
p50/Cdc37, HOP/Sti1, p23, Aha1) modulate the rate of Hsp90-
mediated ATP hydrolysis, thereby regulating the rate of the
chaperone cycle and tailoring Hsp90 chaperone activity to thelecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Inc. 317
Figure 1. The N Domain of Yeast and
Human Hsp90 Is SUMOylated In Vivo
(A) Schematic representation of yHsp90 and
hHsp90a showing the putative N domain SUMO
consensus motif. Proposed SUMO modification
sites are in red.
(B) N domain SUMOylation of wild-type (WT) and
yHsp90-K178R (K178R) was detected by immu-
noblotting with anti-hexahistidine and anti-Smt3
after PreScission Protease digestion.
(C) Yeast cells expressing wild-type (WT) or
yHsp90-K178R (K178R) and carrying SMT3-MYC
underGAL1 promoter were grown on raffinose ()
or galactose (+). Hsp90 modification by Smt3-
Myc was assessed by immunoblotting Hsp90
pull-downs.
(D) SUMOylation of N domain wild-type (WT)
FLAG-hHsp90a and K191R mutant. Hsp90 pro-
teins were immunoprecipitated, subjected to
PreScission Protease digestion, and immuno-
blotted with anti-FLAG and anti-SUMO-1. Lysates
from cells transfectedwith empty plasmid (C) were
used as a control. See also Figure S1.
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2010; Siligardi et al., 2004). Importantly, Aha1, by facilitating en-
ergy-intensive conformational changes necessary to establish
Hsp90 ATPase competence, markedly stimulates the weak
endogenous ATPase activity of Hsp90 and is thus considered
to be a crucial component of active Hsp90 chaperone com-
plexes (Li et al., 2013; Lotz et al., 2003; Panaretou et al., 1998).
In Saccharomyces cerevisiae, the abundance of Hsp90 far ex-
ceeds that of its cochaperones (http://yeastgfp.yeastgenome.
org/). Thus, mechanisms must exist to facilitate the controlled
interaction of these proteins at sites of chaperone activity.
Eukaryotic Hsp90 is subject to numerous posttranslational modi-
fications (PTMs) that play significant roles in regulating associa-
tion and dissociation of specific cochaperones (Mollapour and
Neckers, 2012; Muller et al., 2013; Soroka et al., 2012; Walton-
Diaz et al., 2013; Xu et al., 2012). SUMOylation is a reversible
PTM in which small ubiquitin-like modifier (SUMO) proteins are318 Molecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Inc.covalently linked to lysine residues in a
process similar to ubiquitination and, in
doing so, affect the conformation, pro-
tein-protein interaction, or subcellular
location of the modified protein (Hickey
et al., 2012; Ulrich, 2009). Although
SUMOylation of yeast Hsp82 (yHsp90)
and human Hsp90a (hHsp90a) has been
reported previously (Panse et al., 2004;
Pountney et al., 2008; Zhou et al., 2004),
identification of individual SUMOylated
lysine residues and their impact on
Hsp90 function remains unexplored.
Here, we report that SUMOylation of an
N domain lysine conserved in both
yeast and human Hsp90 initiates re-
cruitment of Aha1 to the chaperone com-
plex in cells. Unexpectedly, N domainSUMOylation also facilitates binding of Hsp90 inhibitors and
sensitizes yeast and mammalian cells to these drugs.
RESULTS
Identification of a SUMOylated Lysine in the Hsp90 N
Domain
We identified a conserved lysine residue (K178) in the N domain of
yeast Hsp82 (yHsp90) that is within the SUMO recognition motif
J-K-x-D/E (J is a hydrophobic amino acid and x is any amino
acid) (Sampson et al., 2001) (Figure 1A). K178, in the N-terminal
domain (open ATP lid), is situated in a solvent-exposed loop and
thus is potentially susceptible to posttranslational modification
(ProteinDataBank [PDB] IDcode1AMW), although the side-chain
amine of K178 makes a series of interactions with the main-chain
carbonyl groups of I20, F128, and L129. In the closed state (PDB:
2CG9), however, K178 becomes buried in the N-terminal
Molecular Cell
Hsp90 SUMOylation Regulates Chaperone Activitydimerization interface, and the side-chain amineofK178becomes
hydrogen bonded to one of the two carboxyl side-chain oxygens
of D132 and to the main-chain carbonyl oxygens of A131 and
F128. Thus, posttranslational modification of K178 is likely only
possible prior to ATP lid closure and N domain dimerization, but
modification of this residue also appears to require additional
conformational changes not visible in these crystal structures.
To ascertain whether this residue is SUMOylated in cells and to
determine if it was the only SUMOylated residue in the yHsp90 N
domain, we mutated K178 to nonSUMOylatable arginine. We
also introduced a PreScission Protease cleavage site between
the N domain and adjacent charged linker region of both wild-
type yHsp90 and yHsp90-K178R, allowing us to separate the N
domain from the full-length Hsp90 protein (which is predicted
to have additional SUMOylation sites in other domains) (Fig-
ure 1A). These yHsp90 proteins were hexahistidine epitope-
tagged at their N terminus and expressed as the sole copy of
yHsp90 in yeast. It is notable that insertion of a PreScission Pro-
tease site upstream of the N domain did not interfere with the
chaperone activity of wild-type yHsp90 (Figures S1A–S1D avail-
able online). The hexahistidine epitope tag allowed us to isolate
Hsp90 proteins from cell lysates using Ni-NTA agarose beads.
We then treated the pull-downs with PreScission Protease to
isolate yHsp90 N domains. Western blotting of the isolated N do-
mains with antibodies to both hexahistidine and Smt3 (the only
SUMO protein in yeast) confirmed a slower migrating band to
be SUMOylated yHsp90 (Figure 1B). These data also confirmed
that K178 is the only SUMOylated lysine in the yHsp90 N domain
(Figure 1B). Lysine can also be targeted by other PTMs, including
ubiquitination and acetylation; however, our data suggest that
K178 is only subject to SUMOylation (Figures S1E and S1F).
Smt3 is an essential protein in yeast. To query the impact of
modulating cellular Smt3 expression on yHsp90 SUMOylation,
we overexpressed Myc-epitope-tagged SMT3 under galac-
tose-inducible promoter (GAL1) in yeast expressing either wild-
type yHsp90 or yHsp90-K178R. After inducing SMT3-MYC
expression by growing the cells on galactose media, we could
detect Smt3-modified wild-type yHsp90 N domain, but the N
domain of yHsp90-K178R remained unmodified (Figure 1C).
To determine whether the corresponding lysine residue (K191)
in human Hsp90a (hHsp90a) (see Figure 1A) is also subject to
SUMOylation, we introduced a PreScission site between the N
domain and charged linker of FLAG-tagged wild-type hHsp90a
and hHsp90a-K191R. After verifying equivalent expression of
both proteins in transiently transfected human embryonic kidney
293 (HEK293) cells (Figure 1D), we confirmed SUMOylation of
K191 in the hHsp90a N domain using anti-FLAG and anti-
SUMO-1 (Figure 1D). Mammalian cells express three SUMOpro-
teins: SUMO-1, SUMO-2, and SUMO-3. Reprobing the blot in
Figure 1D with anti-SUMO-2/SUMO-3 did not yield a detectable
signal, suggesting that the hHsp90a N domain is modified only
by SUMO-1 (data not shown). Unlike in yeast, K191 is also
subject to ubiquitination and acetylation (Figures S1G and S1H).
Hsp90 N Domain SUMOylation Recruits the
Cochaperone Aha1
PTMs can facilitate or inhibit interaction of cochaperones with
Hsp90 in cells (Mollapour and Neckers, 2012; Xu et al., 2012).MoTherefore, we examined the impact of N domain SUMOylation
on Hsp90 binding to selected cochaperones. Hsp90 proteins
from yeast cells expressing either hexahistidine epitope-tagged
wild-type yHsp90 or the nonSUMOylatable K178R mutant were
isolated with Ni-NTA agarose, and associating cochaperones
were examined by western blot. Interaction of yAha1 with the
K178R mutant was abrogated (Figure 2A), as was interaction
of nonSUMOylatable hHsp90a-K191R with human Aha1
(hAha1) (Figure 2B). In contrast, nonSUMOylatable yeast and
human Hsp90 proteins readily associated with Cdc37p50,
Sti1HOP, and Sba1p23 (Figures S2A and S2B). Next, we examined
whether overexpression of yeast SMT3-MYC or human SUMO-
1-HA could ameliorate the observed reduction in Aha1
interaction. While overexpression of SMT3-MYC increased
SUMOylation of wild-type yHsp90 (Figure 2C) and enhanced
its interaction with yAha1 (Figures 2D and S2A), it did not restore
yAha1 interaction with yHsp90-K178R (Figure 2D). We observed
comparable results when SUMO-1-HA was coexpressed with
either wild-type hHsp90a or hHsp90a-K191R in COS7 cells (Fig-
ures 2E, 2F, and S2B).
Based on these data, we asked whether Aha1 preferentially
interacts with N domain SUMOylated yHsp90. Yeast Aha1-
FLAG was expressed under its native promoter and immunopre-
cipitated from cells expressing either wild-type yHsp90 or
yHsp90-K178R. After PreScission Protease cleavage, western
blotting for coimmunoprecipitated yHsp90 N domains revealed
a doublet of equal intensity corresponding to SUMOylated and
nonSUMOylated N domains (Figure 2G). Overexpression of
SMT3-MYC enhanced the interaction of yAha1 with yHsp90
and proportionately enhanced the intensity of the yHsp90 N
domain doublet (Figure 2G). These data, together with the lack
of detectable yAha1 binding to yHsp90-K178R, suggest a model
in which yAha1 is recruited to asymmetrically SUMOylated
yHsp90. Although it is not possible to detect yAha1 interaction
with yHsp90-K178R under steady-state conditions (or even
when yAHA1 is overexpressed using its native promoter), asso-
ciation with yHsp90-K178R is detectable upon strong overex-
pression of yAHA1 (using a GAL1 promoter on a yeast episomal
plasmid; see Supplemental Information) (Figure 2H). This is
consistent with binding data obtained using bacterially ex-
pressed (thus lacking posttranslational modifications) and puri-
fied yAha1 and yHsp90 proteins. In vitro, the affinities of both
wild-type yHsp90 and yHsp90-K178R proteins for yAha1 were
similar (wild-type yHsp90 KD = 0.42 ± 0.08 mM; yHsp90-K178R
KD = 1.1 ± 0.1 mM); Figures S2C and S2D, respectively). These
data are in agreement with previously published values (Xu
et al., 2012). They confirm that K178 mutation does not structur-
ally compromise yHsp90, and they are consistent with the ability
of yHsp90-K178R to support yeast viability (Figures S1A–S1D).
Detectable Aha1 Binding to Hsp90 in Cells Requires
SUMOylation of One Protomer
Our data suggest that, in cells, yAha1 may interact with yHsp90
in which only one of the protomers is SUMOylated on K178 (Fig-
ure 2G). To explore this possibility further, we coexpressed two
copies of yHsp90 (with a PreScission cleavage site as in Fig-
ure 1A) in yeast, with one copy carrying a hexahistidine (His6)
tag and the other copy carrying a GLU/GLU (GLU) epitope tag.lecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Inc. 319
Figure 2. Aha1 Binds to N Domain
SUMOylated Hsp90
(A) Protein extracts from control (C), wild-type
yHsp90 (WT), and nonSUMOylatable yHsp90-
K178R (K178R)-expressing cells were precipi-
tated using Ni-NTA agarose, and yAha1 interac-
tion was detected by immunoblotting.
(B) COS7 cells were transfected with
empty plasmid (C), FLAG-hHsp90a (WT), or
nonSUMOylatable hHsp90a-K191R constructs.
hAha1 interaction with these Hsp90 proteins
was examined by immunoprecipitation (IP) and
immunoblotting.
(C) Yeast cells expressing wild-type yHsp90 (WT)
or yHsp90-K178R (K178R), and carrying GAL1-
SMT3-MYC plasmid, were grown on raffinose ()
or galactose (+). N domain modification (*) by
Smt3-Myc was assessed following precipitation
with Ni-NTA agarose, PreScission Protease
digestion, and immunoblotting.
(D) yAha1 interaction with wild-type yHsp90 (WT)
or yHsp90-K178R (K178R) from cells over-
expressing GAL1-SMT3-MYC and grown on
raffinose () or galactose (+) was assessed
following Ni-NTA agarose pull-down and immu-
noblotting.
(E) COS7 cells transiently transfected with
FLAG-hHsp90a (WT) or nonSUMOylatable
hHsp90a-K191R were cotransfected with SUMO-
1-HA or empty plasmid. N domain hHsp90a
modification (*) by SUMO-1-HA was assessed
following IP, PreScission Protease digestion, and
immunoblotting.
(F) hAha1 interaction with wild-type or non-
SUMOylatable Hsp90 treated as in (E) was
examined following IP and immunoblotting.
(G) Yeast cells expressing yHsp90 (WT) or
yHsp90-K178R (K178R), and coexpressing
yAha1-FLAG and GAL1-SMT3-MYC plasmid,
were grown on raffinose () or galactose
(+). yAha1-FLAG was immunoprecipitated with
anti-FLAG-agarose, and yAha1 interaction with
SUMOylated (*) and nonSUMOylated yHsp90 was
assessed by immunoblotting.
(H) NonSUMOylatable yHsp90-K178R-expressing
cells were transformed with empty plasmid (C) or
multicopy plasmid expressing yAha1-FLAG under
native promoter (Nat) or GAL1 promoter (GAL).
yHsp90-His6 was isolated by Ni-NTA agarose pull-
down, and yAha1-FLAG interaction was examined
by immunoblotting. See also Figure S2.
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equal expression of both epitope-tagged yHsp90 proteins (Fig-
ure 3A, top two panels). Next, we isolated yHsp90-His6 using
Ni-NTA agarose, followed by elutionwith imidazole and immuno-
precipitation with antibody recognizing the GLU/GLU epitope
tag (Figure 3A, middle panel). Immobilized yHsp90-His6/
yHsp90-GLU (WTHis6/WTGLU) heterodimers were then treated
with PreScission Protease in order to isolate the yHsp90 N
domains (Figure 3A, cartoon of flow scheme). Similar experi-
ments were conducted with yeast expressing combinations of
wild-type and K178R yHsp90 or yHsp90-K178R only (e.g.,
WTHis6/K178RGLU; WTGLU/K178RHis6; K178RHis6/K178RGLU).
After protease cleavage, western blotting with anti-His6 or anti-320 Molecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier IncGLU/GLU identified a doublet of equal intensity for WTHis6/
WTGLU samples (Figure 3A, bottom two panels, first lane). In
the WTHis6/K178RGLU and K178RHis6/WTGLU samples, the tag
antibody recognizing the wild-type protomer also identified a
doublet of equal intensity, while the tag antibody recognizing
the mutated protomer identified only a single band whose
molecular weight is consistent with lack of SUMOylation (Fig-
ure 3A, bottom two panels, lanes 2 and 3). Finally, when
yHsp90 was comprised of two mutated protomers, antibodies
recognizing either tag identified a single unmodified species (Fig-
ure 3A, bottom two panels, lane 4).
These data suggest that a nonSUMOylated yHsp90 protomer
readily dimerizes with either another nonSUMOylated protomer.
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explore the possibility that two SUMOylated protomers might
dimerize, we immunoprecipitated Smt3-Myc from yeast lysates
expressing wild-type yHsp90His6. The immobilized yHsp90
proteins were treated with PreScission Protease, and isolated
N domains were visualized by western blot. If two SUMOylated
protomers dimerized, we would expect the abundance of the
slower-migrating (SUMOylated) N domain to be greater than
that of the faster migrating (nonSUMOylated) species. However,
we always observed a doublet of nearly equal intensity upon
probing with anti-His6 (Figure 3B, upper panel). Probing the
same blot with anti-Myc confirmed that the slower-migrating
band reflected SUMOylated yHsp90 (Figure 3B, middle panel).
These findings prompted us to reexamine yAha1 binding to
SUMOylated yHsp90. We immunoprecipitated FLAG-yAha1
from yeast cells overexpressing SMT3-MYC followed by
PreScission Protease treatment to isolate N domains of the
coimmunoprecipitated His6- or GLU-tagged yHsp90 proteins.
We verified that yAha1 does not bind to yHsp90 comprised
of two nonSUMOylated protomers (Figure 3C, lane 4),
and we confirmed that the cochaperone binds with equal
efficiency to a yHsp90 molecule comprised of either one
wild-type and one K178R protomer (Figure 3C, lanes 2 and 3)
or two wild-type protomers (Figure 3C, lane 1). These data
provide further evidence that SUMOylation of one Hsp90 pro-
tomer is necessary and sufficient for optimal yAha1 recruitment
in yeast cells.
To determine whether ATP-binding affects Hsp90 N domain
SUMOylation, we examined two well-characterized yHsp90
mutants: E33A, which efficiently binds, but poorly hydrolyzes,
ATP (the equivalent hHsp90 mutant displays increased Aha1
association in cells; Xu et al., 2012), and D79N, which does not
bind ATP (Obermann et al., 1998; Panaretou et al., 1998). We ex-
pressed both hexahistidine-tagged mutants and wild-type
yHsp90 in yeast cells, and we examined their steady-state N
domain SUMOylation after affinity pull-down and PreScission
cleavage. N domain SUMOylation of yHsp90-E33A was
markedly greater than that of wild-type yHsp90. In contrast, N
domain SUMOylation of yHsp90-D79N was not detectable (Fig-
ure 3D). These data suggest that ATP binding to Hsp90 is an
important prerequisite for N domain SUMOylation, consistent
with the requirements for optimal Aha1 association. This model
predicts that N domain deSUMOylation occurs prior to initiation
of a new chaperone cycle.
Loss of Hsp90 N Domain SUMOylation Minimally Affects
Several Hsp90-Dependent Clients
Protein SUMOylation impacts numerous biological pathways,
including nuclear-cytoplasmic transport, cell cycle control, and
stress responses (Johnson, 2004; Ulrich, 2009). However, we
found that neither a factor-mediated G1 arrest nor heat shock
caused an increase in steady-state yHsp90 N domain
SUMOylation (Figure S3A), and yeast expressing only yHsp90-
K178Rmounted a normal transcriptional response to heat shock
(Figure 4A). Likewise, yeast cells expressing yHsp90-K178R
displayed no growth or cell cycle defects (Figures S3B–S3D),
nor did this mutation affect nuclear or cytoplasmic distribution
of yHsp90-GFP (data not shown).MoWhen we queried the ability of yHsp90-K178R or
hHsp90a-K191R to interact with and chaperone several Hsp90
clients previously reported to require Aha1/Hsp90 association
(Lotz et al., 2003; Panaretou et al., 2002), we found that this
mutation failed to affect Hsp90-dependent chaperoning of the
glucocorticoid receptor (GR) or the active form of Ste11 kinase
(Ste11DN), the ortholog of mammalian Raf-1 (Flom et al., 2008;
Louvion et al., 1998) (Figures 4B and 4C). Similarly,
hHsp90a-K191R associated with GR and Raf-1 equivalently to
wild-type hHsp90a (Figure 4D). NonSUMOylatable yeast and
human Hsp90 proteins also interacted with and chaperoned
v-Src with efficiency equal to that of wild-type Hsp90 (Figures
4E and 4F). These data suggest that the attenuated interaction
of yHsp90-K178R with yAha1 does not phenocopy yaha1 dele-
tion (Lotz et al., 2003; Panaretou et al., 2002). This was further
supported by comparing the growth of yeast expressing either
yHsp90-K178R or wild-type yHsp90 but lacking yAha1 expres-
sion on glucose (YPDA) and respiratory (YPEG) growth media
at an elevated temperature. As previously reported (Lotz et al.,
2003; Panaretou et al., 1998), yaha1D cells displayed a
temperature sensitivity phenotype on YPDA and YPEG media
(Figure S3E). In contrast, yeast expressing yHsp90-K178R
displayed no growth defects on either media, consistent with
the possibility that Aha1 may have Hsp90-independent activity
(Sun et al., 2012).
Aha1 stimulates Hsp90-mediated ATP hydrolysis and thus
reduces the dwell time of clients in the chaperone complex,
which has deleterious consequences for difficult-to-fold clients
that require prolonged association with Hsp90 (such as the
cystic fibrosis transmembrane conductance regulator protein,
CFTR) (Loo et al., 1998; Youker et al., 2004). We examined the
ability of nonSUMOylatable yHsp90 to promote CFTR stabiliza-
tion and maturation. Yeast cells were cotransfected with HA-
tagged CFTR (under the control of a constitutive promoter) and
either wild-type yHsp90 or yHsp90-K178R, and we determined
the rate of CFTR protein decay in the presence of cycloheximide.
We found CFTR stability to be significantly enhanced in yeast
expressing yHsp90-K178R compared to wild-type cells (Fig-
ure 4G). A similar result was obtained in HEK293 cells transiently
transfected with wild-type CFTR and with either wild-type
hHsp90a or hHsp90a-K191R. The greater abundance of slower
migrating CFTR in cells overexpressing hHSP90a-K191R (Fig-
ure 4H) is consistent with previous observations that reduced
Aha1 expression improves Hsp90-dependent CFTR maturation,
presumably by allowing prolonged interaction of this difficult-to-
fold client with Hsp90 (Wang et al., 2006). Thus, the enhanced
CFTR chaperone efficiency of N domain lysine-mutated Hsp90
in both yeast and mammalian cell backgrounds likely reflects
a physiological consequence of compromised Hsp90/Aha1
interaction.
Increased SUMOylation of the Hsp90 N Domain Inhibits
Chaperone Function
Overexpression of SMT3 and SUMO-1 increased N domain
SUMOylation of yHsp90 and hHsp90a, respectively (Figures
2C and 2E). In contrast to lack of SUMOylation, increased
SUMOylation of the Hsp90 N domain more generally affected
Hsp90 chaperone activity. Overexpression of SMT3-MYClecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Inc. 321
Figure 3. Aha1 Binds to Asymmetrically SUMOylated Hsp90
(A) Lysates from yeast cells overexpressing GAL1-SMT3-MYC and coexpressing wild-type yHsp90 (WT) or yHsp90-K178R (K178R) with either a His6 or a GLU
epitope tag (as indicated) were used to first precipitate His6-yHsp90 with Ni-NTA agarose. Eluates were subsequently used to immunoprecipitate GLU epitope-
tagged yHsp90. After PreScission Protease digestion, N domain SUMOylation was assessed by immunoblotting.
(B) Smt3-Myc was immunoprecipitated from wild-type yeast cells (WT) grown on either raffinose () or galactose (+). Immunoprecipitated Smt3-Myc and Smt3-
Myc-modified proteins were treated with PreScission Protease, and N domain SUMOylation of Smt3-Myc coprecipitated Hsp90 proteins was assessed by
immunoblotting.
(legend continued on next page)
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Figure 4. Lack of yHsp90 N Domain
SUMOylation Has Little Effect on Most
Hsp90 Clients
(A) Wild-type (WT) or yHsp90-K178R (K178R)-
expressing yeast strains were heat shocked
(40 min at 39C). Heat shock response was
measured in three independent experiments. All
data represent mean ± SD.
(B) GR-lacZ activity was assessed in the same
yeast strains as above. Data are expressed as a
percentage of the activity observed in wild-type
cells and depicted as the mean ± SD from values
obtained in three independent experiments.
(C) Wild-type (WT) and yHsp90-K178R (K178R)
yeast strains coexpressing Ste11DN-His6 under
GAL1 promoter were grown on raffinose () or
galactose (+) media, and Ste11DN-His6 protein
expression was examined by immunoblotting.
a-tubulin was used as loading control.
(D) COS7 cells were transfected with indicated
FLAG-Hsp90a constructs. Hsp90 was immuno-
precipitated with anti-FLAG agarose; coprecipi-
tating (endogenous) GR and Raf-1 proteins were
detected by immunoblotting.
(E) Wild-type (WT) and yHsp90-K178R (K178R)
yeast containing v-SRC under GAL1 promoter
were grown on raffinose () or galactose (+)
media. v-Src and total phosphotyrosine were
detected by immunoblotting.
(F) NIH 3T3 cells stably expressing v-Src protein
were transfected with empty plasmid (C), FLAG-
hHsp90a (WT), or FLAG-hHsp90a-K191R (K191R)
constructs. v-Src protein was immunoprecipi-
tated, and associated FLAG-Hsp90 proteins were
detected by immunoblotting.
(G) CFTR-HA was expressed in wild-type (WT) or
yHsp90-K178R yeast; cells were treated with
cycloheximide (CHX, 50 mM) and harvested at the
indicated time points. CFTR was analyzed by
immunoblotting.
(H) HEK293 cells were transfected with wild-type CFTR and cotransfected with either wild-type FLAG-hHsp90a (WT) or FLAG-hHsp90a-K191R (K191R)
constructs. After 24 hr, CFTR and FLAG-hHsp90a were detected by immunoblotting. a-tubulin was used as loading control. See also Figure S3.
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Hsp90 SUMOylation Regulates Chaperone Activityreduced CFTR stability in wild-type yeast, but not in yeast
expressing yHsp90-K178R (Figures 5A and S4). Overexpression
of SUMO-1 in HEK293 cells cotransfected with CFTR and FLAG-
tagged hHsp90a proteins had a similar effect (Figure 5B).
Likewise, we found that SMT3-MYC overexpression in wild-
type yeast led to both reduced v-Src expression and v-Src-
mediated protein tyrosine phosphorylation (Figure 5C) as well
as a 70% reduction in GR activity (Figure 5D), but this was not
seen in yeast expressing yHsp90-K178R.
Finally, we studied the effect of SUMOylation on Hsf1
transcriptional activity. It is generally accepted that Hsp90
interaction suppresses Hsf1 activity (Zou et al., 1998), and
compromised Hsp90 chaperone function, due to mutation or
pharmacologic inhibition, leads to induction of Hsf1 activity in
yeast even in the absence of heat shock (Hjorth-Sørensen
et al., 2001). SMT3-MYC overexpression caused a heat shock(C) Yeast cells in (A) coexpressing yAha1-FLAG under native promoter were u
coprecipitated Hsp90 were then isolated by PreScission Protease digestion and
(D) Wild-type yHsp90-His6 (WT), yHsp90-E33A-His6 (E33A), or yHsp90-D79N-H
yHsp90. After Ni-NTA agarose pull-down and PreScission Protease digestion, N
Moresponse in wild-type yeast, but not in yeast expressing
yHsp90-K178R (Figure 5E). Similarly, we observed that the
Hsp90 inhibitors geldanamycin (GA) and radicicol (RD) failed to
induce a heat shock response in yHsp90-K178R-expressing
yeast (Figure 5F). Importantly, mutation of K178 did not affect
the heat shock response induced by elevated temperature (Fig-
ure 4A). These data indicate that N domain SUMOylation differ-
entially affects the heat shock transcriptional response to
elevated temperature and Hsp90 inhibitors, and they suggest
possible similarities between deregulated Hsp90 SUMOylation
and pharmacologic inhibition of the chaperone.
N Domain SUMOylation Sensitizes Cells to Hsp90
Inhibition
To explore the possible impact of Hsp90 SUMOylation on
drug sensitivity, we first examined effects of GA and RD onsed to immunoprecipitate yAha1 with anti-FLAG agarose. N domains from
analyzed by immunoblotting.
is6 (D79N) constructs were expressed in yeast cells containing endogenous
domain SUMOylation was assessed by immunoblotting.
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Figure 5. Increased Hsp90 N Domain
SUMOylation Affects Chaperone Function
(A) Wild-type (WT) or yHsp90-K178 (K178R) yeast
cells coexpressing CFTR-HA and GAL1-SMT3-
MYC were grown on raffinose () or galactose (+)
media, treated with cycloheximide (CHX, 50 mM),
and harvested at the indicated time points. CFTR
was visualized by immunoblotting.
(B) HEK293 cells were transfected with wild-type
CFTR and cotransfected with empty plasmid
(C), wild-type FLAG-hHsp90a (W), or FLAG-
hHsp90a-K191R (R), with (+) or without ()
cotransfection of SUMO-1-HA. After 24 hr, CFTR,
FLAG-hHsp90a, and SUMO-1-HA were detected
by immunobloting. a-tubulin was used as loading
control.
(C) Wild-type (WT) and yHsp90-K178R (K178R)-
expressing yeast containing GAL1-v-SRC and
GAL1-SMT3-MYC were grown on raffinose () or
galactose (+) media. v-Src, total phosphotyrosine,
and Smt3-Myc were detected by immunoblotting.
(D) GR-lacZ activity was assessed in wild-type (W)
and yHsp90-K178R (R) yeast cells that also
expressed GAL1-SMT3-MYC. Cells were grown
on raffinose () or galactose (+) media. Data are
expressed as a percentage of the activity
observed in wild-type cells and depicted as the
mean ± SD of three independent experiments.
(E) Heat shock element (HSE)-lacZ reporter was
used to monitor the heat shock response in yeast
expressing wild-type yHsp90 (WT) or yHsp90-
K178R (K178R); yeast also expressedGAL-SMT3-
MYC. Cells were grown on raffinose () or
galactose (+) media and heat shocked (40 min at
39C). All data represent mean ± SD of three
independent experiments.
(F) Wild-type yHsp90 (WT) and yHsp90-K178R
(K178R) cells were treated with GA (+; 50 mM, 1 hr)
or RD (+; 30 mM, 1 hr). Heat shock response was
measured from three independent experiments.
All data represent mean ± SD. See also Figure S4.
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factor and heat shock (Figure S3A), N domain SUMOylation
increased following exposure to GA or RD (Figure 6A). Since
these drugs did not affect endogenous Smt3 expression, we
reasoned that they might preferentially interact with, and confor-
mationally trap, N domain SUMOylated Hsp90. We tested this
possibility by overexpressing SMT3-MYC in wild-type yHsp90-
expressing and yHsp90-K178R-expressing cells and using bio-
tinylated Hsp90 inhibitor ganetespib and streptavidin beads to
affinity purify yHsp90 proteins from cell lysates. We found that
SMT3 overexpression clearly enhanced ganetespib recognition
of wild-type yHsp90 but had little effect on recognition of
yHsp90-K178R (Figure 6B).
Based on these observations, we asked whether increased N
domain SUMOylation sensitized yeast cells to Hsp90 inhibition.
Although we saw no difference in drug sensitivity between
cells expressing wild-type yHsp90 or yHsp90-K178R under
normal conditions (Figure 6C, ‘‘C’’ rows), after SMT3 overex-324 Molecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Incpression cells harboring wild-type yHsp90 displayed greater
sensitivity to a panel of four N domain inhibitors compared to
yeast expressing yHsp90-K178R (Figure 6C, ‘‘GAL-SMT3’’
rows). It is notable that, at higher drug concentrations, lack of
SUMOylation does not confer resistance to Hsp90 inhibitors
(Figure S5A).
We carried out similar experiments in mammalian cells. Using
immortalized NIH 3T3 mouse fibroblasts transiently transfected
with plasmids encoding hemagglutinin (HA)-tagged SUMO-1,
SUMO-2, or SUMO-3 proteins, we confirmed that only
SUMO-1 overexpression sensitized the cells to ganetespib, as
evidenced by induction of the proapoptotic markers: cleaved
caspase and cleaved poly (ADP-ribose) polymerase (PARP)
(Figure 6D). Likewise, Hsp90 N domain SUMOylation was
detectable only in SUMO-1-transfected cells. It is notable that
overexpression of SUMO-1 in the absence of Hsp90 inhibitor
did not induce apoptotic markers in NIH 3T3 cells (Figure 6D,
right panel)..
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Hsp90 inhibitors than do their nontumorigenic counterparts
(Bisht et al., 2003). Therefore, we asked whether Hsp90 was
SUMOylated to a greater degree in NIH 3T3 cells stably trans-
formed with either v-Src or mutated (constitutively active) MET
(MET-Y1428H) to a degree greater than that of parental NIH
3T3 cells and whether steady-state Hsp90 N domain SUMOyla-
tion intensity correlated with sensitivity to ganetespib. Indeed,
both transformed cell lines displayed increased Hsp90 N domain
SUMOylation compared to nontransformed cells (Figure 6E), and
oncogenic transformation rendered the cells more sensitive to
ganetespib, as evidenced by a greater abundance of apoptotic
markers (Figure 6F).
These findings suggest that Hsp90 inhibitors and Aha1
compete for binding to SUMOylated Hsp90. To test this possibil-
ity, we overexpressed SMT3-MYC in yeast cells expressing wild-
type yHsp90 and then treated the cells with GA. Interaction of
yHsp90 and yAha1 was examined by Hsp90 pull-down and
western blot. Although SMT3-MYC overexpression increased
yHsp90 interaction with yAha1, association of the cochaperone
with Hsp90 was not detectable in cells treated with GA prior to
lysis (Figure S5B). Finally, we showed earlier (Figure 3D) that
yHsp90-E33A (which binds ATP but does not hydrolyze it) is
SUMOylated markedly more than wild-type yHsp90, and the
equivalent mutation in hHsp90a-E47A promotes increased
steady-state interaction with Aha1 in cells (Xu et al., 2012). How-
ever, GA-affinity bead pull-down of hHsp90a-E47A was less effi-
cient than that of thewild-type protein, and Aha1was not present
in either pull-down (Figure S5C), consistent with the hypothesis
that Hsp90 inhibitors and Aha1 cannot interact concurrently
with N domain SUMOylated Hsp90.
DISCUSSION
In this study, we identified SUMOylation of a conserved lysine
residue in the N domains of both yeast (K178) and human
(K191) Hsp90. Mutation of this residue abrogated N domain
SUMOylation and prevented detectable intracellular interaction
with the ATPase-stimulating cochaperone Aha1. Based on
AHA1 deletion studies in yeast, Aha1/Hsp90 interaction is
considered to be important for the chaperoning of Hsp90 clients,
including those examined in this study (Holmes et al., 2008; Lotz
et al., 2003; Panaretou et al., 2002). However, lack of detectable
Aha1 interaction with yHsp90-K178R engendered observable
effects only with the difficult-to-fold Hsp90 client CFTR, consis-
tent with published reports demonstrating improved Hsp90-
dependent CFTR folding in cells with reduced Aha1 expression
(Koulov et al., 2010; Wang et al., 2006). Our data suggest that
reduced Aha1/Hsp90 interaction per se does not phenocopy
yaha1D, implying that Aha1, like the cochaperones Sba1p23
and Cdc37p50 (Echtenkamp et al., 2011; Kimura et al., 1997),
may have additional activities in cells that are independent of
(but perhaps function in parallel with) its role in modulating
Hsp90 activity (Sun et al., 2012).
In yeast, Aha1 is expressed at a concentration that is 10-fold
lower than that of Hsp90 (Ghaemmaghami et al., 2003). Thus,
although bacterially purified yAha1 binds to wild-type yHsp90
and yHsp90-K178R proteins with comparable affinity, it isMoreasonable to assume that, in cells, certain Hsp90 PTMs modu-
late Aha1 recruitment to active Hsp90 chaperone complexes.
Indeed, phosphorylation and acetylation of specific sites on
Hsp90 have been shown previously to affect interaction with
Aha1 (Mollapour et al., 2010, 2011a; Retzlaff et al., 2010; Scrog-
gins et al., 2007). Our current data suggest that N domain
SUMOylation is a PTM able to initiate recruitment of Aha1 to
Hsp90 in both yeast and human cells. One molecule of Aha1 is
sufficient to maximally stimulate Hsp90 ATPase activity (Panare-
tou et al., 2002; Soroka et al., 2012; Xu et al., 2012). The Aha1 N
domain is thought to interact first with the middle domain of
one Hsp90 protomer, after which the Aha1 C domain associates
with the N domain of the opposing protomer (or with a hydrop-
hobic groove formed by transient, ATP-dependent dimerization
of both Hsp90 N domains) (Koulov et al., 2010; Meyer et al.,
2003; Retzlaff et al., 2010). Although, as of yet, we have not
uncovered the mechanism by which Hsp90 N domain
SUMOylation facilitates Aha1 interaction, the asymmetry of this
PTM (and its conservation in yeast and human cells) is consistent
with a role in promoting the asymmetric interaction of Aha1 and
Hsp90 in cells.
Increased SUMOylation of the Hsp90 N domain, although pre-
dicted to accelerate the rate of chaperone cycling, functionally
compromised several Hsp90 clients, including v-Src, GR, and
CFTR. These data are consistent with previous studies exam-
ining the impact of other Hsp90 modifications that stimulate
ATP hydrolysis. Thus, the yHsp90 mutant T22I demonstrates
both enhanced ATPase activity and ATP-dependent N domain
dimerization (Prodromou et al., 2000) while possessing reduced
ability to chaperone both GR and v-Src (Nathan and Lindquist,
1995). Similarly, although covalent N-terminal fusion of constitu-
tively dimerized coiled-coil domains to yHsp90 enforces N
domain proximity and significantly increases basal ATPase
activity and yAha1 binding affinity, coiled-coil yHsp90 chaper-
ones GR and v-Src less efficiently than does wild-type yHsp90
(Pullen and Bolon, 2011).
We explored the temporal relationship between N domain
SUMOylation, ATP binding, and ATP hydrolysis with the help of
two yHsp90 point mutants. yHsp90-E33A efficiently binds, but
does not hydrolyze, ATP. Compared to wild-type yHsp90, this
mutant was markedly more SUMOylated at steady-state. In
contrast, yHsp90-D79N does not bind ATP and was not
detectably SUMOylated. The simplest model that is consistent
with these data suggests that ATP binding is a prerequisite for
N domain SUMOylation. Although we cannot absolutely rule
out the possibility that SUMOylation may also stabilize an
ATP-bound Hsp90 conformation, the fact that SUMOylation of
yHsp90-D79N was not observed reduces the likelihood of this
hypothesis.
Surprisingly, ATP-competitive Hsp90 inhibitors increased
steady-state N domain SUMOylation and readily recognized
wild-type, but not nonSUMOylatable, yHsp90 in protein lysates
of yeast overexpressing SMT3. Since association of Aha1 and
these inhibitors with Hsp90 is mutually exclusive (Figure S5B),
our data suggest that inhibitors preferentially bind to
SUMOylated Hsp90 by displacing previously bound ATP prior
to lid closure and Aha1-facilitated Hsp90 commitment to N
domain dimerization and ATP hydrolysis, by which pointlecular Cell 53, 317–329, January 23, 2014 ª2014 Elsevier Inc. 325
Figure 6. Increased Hsp90 N Domain SUMOylation Sensitizes Cells to Hsp90 Inhibitors
(A) The effects of heat shock (HS) (40 min at 39C), GA (50 mM, 1 hr), or RD (30 mM, 1 hr) on SUMOylation of yHsp90-K178 (*) were monitored by immunoblotting
with anti-hexahistidine. Unconjugated Smt3 was detected by anti-Smt3.
(B) Yeast cells expressing wild-type yHsp90 (WT) or yHsp90-K178R (K178R), and harboring GAL1-SMT3-MYC, were grown on galactose. Hsp90 was isolated
from yeast lysates by incubating with indicated amounts of biotinylated ganetespib followed by streptavidin agarose beads and detected by immunoblotting with
anti-His6.
(C) Wild-type or K178R-yHsp90-expressing yeast harboringGAL1-SMT3-MYCwas grown on galactose media for 4 hr. A 1:10 dilution series of 107 cells/ml were
spotted on YPDA agar containing indicated concentrations of the Hsp90 inhibitors GA, RD, SNX (SNX2112), or GB (ganetespib). Plates were incubated at 28C
for 4 days.
(legend continued on next page)
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Figure 7. Hsp90 SUMOylation Facilitates Aha1 Association but Also
Enhances Binding of ATP-Competitive Inhibitors
(1) The Hsp90 chaperone cycle is initiated by ATP binding to N domain(s). (2)
This promotes asymmetric N domain SUMOylation. (3) Hsp90 inhibitors
preferentially bind to SUMOylated Hsp90 by replacing ATP in the nucleotide
binding pocket. (4) In the absence of N domain inhibitors, asymmetric N
domain SUMOylation facilitates Aha1 association, accelerating the ATPase-
driven Hsp90 chaperone cycle. (5) SUMOylation is dynamic, and Hsp90 de-
SUMOylation is predicted to occur prior to initiation of a new chaperone cycle.
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sible to these drugs. Drug binding to Hsp90 prevents N domain
dimerization and Aha1 recruitment, trapping SUMOylated Hsp90
in an ‘‘open’’ conformation, unable to proceed further in the
chaperone cycle (Figure 7). This model is consistent with a pre-
vious report that Aha1 knockdown sensitizes cancer cells to
Hsp90 inhibitors (Holmes et al., 2008) and with our finding that
the hydrolysis-incompetent yHsp90-E33A, which is trapped in
an ATP-bound, lid-closed conformation, is SUMOylated to a
degree greater than that of wild-type yHsp90 yet is poorly recog-
nized by Hsp90 inhibitor (Figure S5C). Perhaps unexpectedly,
this model predicts that Hsp90 inhibitors do not bind to all N
domain undimerized (open) Hsp90 conformations with equal(D) NIH 3T3 cells were transfected with empty plasmid (C), SUMO-1-HA, SUMO-2
ganetespib for an additional 6 hr. SUMO-1, SUMO-2, and SUMO-3, hHsp90a N d
immunoblotting.
(E) Parental NIH 3T3 cells and NIH 3T3 stably expressing v-Src or constitutively
(containing a PreScission cleavage site). After 24 hr, N domain SUMOylation (*)
PreScission Protease digestion.
(F) Parental NIH 3T3 cells and NIH 3T3 cells stably expressing v-Src or constitu
ganetespib for 6 hr. Cleaved PARP and cleaved caspase-3 were detected by im
Moaffinity but can distinguish ATP-boundHsp90 (prior to lid closure)
from the ATP-unbound chaperone.
Finally, since Hsp90 inhibitors have binding constants
much higher than those of ATP, this model predicts that drug
trapping of SUMOylated Hsp90 preferentially removes a fraction
of the actively cycling chaperone pool. Our observation that the
intensity of Hsp90N domain SUMOylation increases with cellular
transformation is consistent with this proposal and provides
mechanistic insight that helps clarify an observation made
some years ago by Kamal et al. (2003), experimentally supported
by subsequent studies but still not satisfactorily explained, that
Hsp90 isolated from tumor cells simultaneously demonstrates
both ATPase activity and affinity for Hsp90 inhibitors greater
than those of Hsp90 isolated from nontransformed cells.
The tumor cell selectivity of these drugs thus may reflect a
greater dependence of cancer cells (relative to nontransformed
cells) on the constitutive engagement of a significant fraction of
Hsp90 in the chaperone cycle.
EXPERIMENTAL PROCEDURES
Yeast Strains, Plasmids, and Growth Media
Yeast strain pp30 (MAT a, trp1-289, leu2-3,112, his3-200, ura3-52, ade2-101,
lys2-801, hsc82KANMX4, hsp82KANMX4) was used in this study (Panaretou
et al., 1998). Plasmids were constructed as described previously (Mollapour
et al., 2011b). Detailed procedures, a list of primers (Table S1), and media
conditions for both yeast and mammalian cells are provided in the Sup-
plemental Information.
Protein Extraction, Immunoprecipitation, PreScission Protease
Cleavage, and Immunoblotting
Total protein extracts were prepared and analyzed by western blotting
as described previously (Mollapour et al., 2010), with the exception
that N-ethylmaleimide (NEM, 20 mM) was included in the protein lysis
buffer. Detailed methods for protein precipitations, cleavage by Pre-
Scission Protease, and detection by western blotting for both yeast and
mammalian systems are presented in the Supplemental Experimental
Procedures.
Assays for Hsp90 Client Activity
v-Src induction and activation were analyzed as described previously (Molla-
pour et al., 2011b). Expressed v-Src protein was detected with EC10 mouse
antibody (Millipore) and v-Src activity with 4G10 mouse anti-phosphotyrosine
(Millipore). GR assay was performed as described previously (Garabedian and
Yamamoto, 1992), as was measurement of HSE-LacZ expression (Hjorth-
Sørensen et al., 2001). Ste11DN induction was analyzed as described
previously (Flom et al., 2008; Louvion et al., 1998). Ste11DN plasmid is a gift
of Jill Johnson. Additional details are found in the Supplemental Experimental
Procedures.
Isothermal Titration Calorimetry and KD Determinations
Isothermal titration calorimetry (ITC) and KD determinations were performed as
described previously (Prodromou et al., 2000). Additional information can be
found in the Supplemental Experimental Procedures.-HA, or SUMO-3-HA. After 24 hr, cells were treated with either 0.5 mMor 1.0 mM
omain SUMOylation, cleaved PARP, and cleaved caspase-3 were detected by
active MET (Y1248H) mutant were transfected with wild-type FLAG-hHsp90a
of FLAG-hHsp90a was assessed by immunoblotting with anti-FLAG following
tively activated MET (Y1248H) mutant were treated with indicated amounts of
munoblotting. a-tubulin was used as a loading control. See also Figure S5.
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five figures, and one table and can be found with this article online at http://
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